Novartis To Submit Exelon Patch By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis plans to submit a transdermal patch formulation of its Alzheimer's disease therapy Exelon (rivastigmine) by year-end, the firm said July 19